Opinion|Videos|November 28, 2025
Nonstatin Therapy Decisions
Panelists discuss how nonstatin agents are chosen and when combination therapy should be introduced for high-risk patients.
Episodes in this series
Panelists discuss how clinicians decide when to introduce nonstatin low-density lipoprotein (LDL)–lowering agents such as ezetimibe or PCSK9 inhibitors. The choice depends on residual LDL levels, patient risk category, and prior therapy response.
They emphasize early combination therapy for high-risk patients, noting that waiting for repeated therapy failures delays optimal outcomes.
Panelists stress that structured treatment algorithms and patient follow-up can ensure timely intensification and reduce long-term cardiovascular risk.
Related to this article
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
3
Drug Price Drives Value of MASH Therapies More Than Efficacy
4
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
5